Skip to main content

Viskase Holdings, Inc.

corporate_fare Company Profile

Viskase Holdings, Inc.

ENZN·OTC·Life Sciences·CIK 0000727510

Enzon Pharmaceuticals, Inc. is a public company acquisition vehicle, incorporated on May 11, 1983. Historically, the company generated royalty revenues from licensing agreements with other companies. These revenues were primarily related to sales of drug products that utilized Enzon's proprietary technology. For over ten years, Enzon has not conducted clinical operations and has maintained limited corporate operations. The company previously had a marketing agreement for the drug Vicineum, which could have generated future milestone and royalty payments if approved. However, the licensee for Vicineum was canceled by the counterparty to the marketing agreement, and Enzon's patent for Vicineum has since expired. Consequently, Enzon does not expect to earn any future material revenue from this product. On June 20, 2025, Enzon, EPSC Acquisition Corp. (a wholly owned subsidiary of Enzon), and Viskase Companies, Inc. entered into an Agreement and Plan of Merger, which was amended on October 24, 2025. Under this agreement, EPSC Acquisition Corp. will merge into Viskase, with Viskase surviving as a wholly owned subsidiary of Enzon. Following the merger, Enzon's pre-closing stockholders, including holders of its Series C Non-Convertible Redeemable Preferred Stock, are anticipated to hold 45% of Enzon's outstanding Common Stock, while Viskase's pre-closing stockholders will hold 55%.

Viskase Holdings, Inc. (OTC:ENZN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ENZN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Enzon Commences Exchange Offer for Preferred Stock Ahead of Viskase Merger
  • Enzon Files S-4 for Merger with Viskase, Proposing 1-for-100 Reverse Stock Split and Significant Dilution for Existing Common Shareholders

Financial Snapshot

Quarter ended November 12, 2025
Net Income
-$824K
Diluted EPS
-$0.02
Op. Cash Flow
-$2.33M
Operating Income
-$1.3M
Cash & Equivalents
$43.26M
Debt / Equity
0.00×
Shares Outstanding
74.21M sh
Source: 10-Q · filed 2025-11-12 · accession 0001104659-25-110410

Recent Capital Actions

  • 2026-02-11 Proposed Exchange Offer +0 sh

    filed with the Securities and Exchange Commission (the “SEC”) on January 30, 2026 (as hereby amended and supplemented and together with any subsequent amendments and supplements thereto, this “Schedule TO”), is filed by…

  • 2026-01-30 Proposed Cash ↑ +$24.9M

    eeds of approximately $25.0 million pursuant to securities purchase agreements entered into in December 2025 and January 2026. $0.1 million of specific incremental costs were incurred attributable to the offerings of…

Detected from SEC filings (8-K, S-4, POS AM, 6-K). Last 12 months.

No longer listed

ENZN (Viskase Holdings, Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed ENZN - Filings & News (Page 2)

ENZN
Jan 30, 2026, 3:13 PM EST
Filing Type: S-4/A
Importance Score:
7
ENZN
Jan 28, 2026, 5:01 PM EST
Filing Type: S-4
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets